<DOC>
	<DOCNO>NCT02095860</DOCNO>
	<brief_summary>The purpose study ass effect high fat meal light meal blood level Daclatasvir , Asunaprevir BMS-791325 administration 3 drug fixed-dose combination healthy subject .</brief_summary>
	<brief_title>Food Effect Fixed Dose Combination Daclatasvir , Asunaprevir BMS-791325</brief_title>
	<detailed_description>IND Number : 100,932/79,599/101,943 Primary Purpose : Other : Phase 1 clinical pharmacology bioavailability study ass food effect</detailed_description>
	<mesh_term>Hepatitis C</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Healthy male female subject age 18 49 year , inclusive . Women childbearing potential must use acceptable method contraception least 4 week prior study drug administration . Any significant acute chronic medical illness Current recent ( within 3 month study drug administration ) gastrointestinal disease Any gastrointestinal surgery could impact upon absorption study drug , include cholecystectomy History biliary disorder , include Gilbert 's syndrome DubinJohnson disease Use tobaccocontaining nicotinecontaining product Any follow 12lead electrocardiogram ( ECG ) prior study drug administration , confirm repeat : PR ≥210 msec QRS ≥120 msec QT ≥500 msec QTcF ≥450 msec Any follow laboratory result outside range specify prior study drug administration , confirm repeat : Alanine aminotransferase ( ALT ) &gt; Upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) &gt; ULN Total bilirubin ( TBILI ) &gt; ULN Creatinine &gt; ULN</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>